Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease

GlaxoSmithKlineGSK announced that it has made a new offer to supplyits rotavirus vaccine, RotarixTM, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices. This announcement is part of the company's efforts to increase access to its medicines and vaccines in the world's poorest countries. It is estimated that more than half a million children die of rotavirus gastroenteritis each year - the equivalent of a child a minute worldwide(1) - and it is responsible for the hospitalization of millions more.(2)

GSK's offer has been made in response to a UNICEF request for rotavirus vaccines and will now be reviewed by UNICEF. If accepted, large scale vaccination against rotavirus could begin later this year. The offer made to UNICEF was developed in consultation with the Bill & Melinda Gates Foundation and The Clinton Health Access Initiative with support from the Pan-American Health Organisation (PAHO), and comes ahead of the GAVI Pledging Conference for Immunisation which will be held in London on 13th June 2011.

This new commitment for RotarixTMfollows the announcement in March 2010 that GSK would supply its pneumococcal vaccine, SynflorixTM, to GAVI at a heavily discounted price through an innovative financing mechanism known as the Advance Market Commitment (AMC). Rotavirus related diarrhea, and pneumococcal disease are the two leading childhood killers in developing countries.(3,4)

Andrew Witty, CEO of GlaxoSmithKline said: "Whilst most babies in the world will get rotavirus at some point, those in developing countries do not have access to the medical care they need which means millions of babies die unnecessarily.GSK is committed to playing its part in addressing the healthcare challenges faced by world's poorest countries. By working in partnership with others including governments, international agencies, NGOs and developing countries, we can find innovative ways to accelerate access to vaccines that are urgently needed by children living in these countries."

Andrew Mitchell, UK Secretary of State for International Development said: "It is unacceptable that in the 21st century a child dies every minute of every day from diarrhoea, a preventable disease. I hugely welcome today's announcement from GSK to reduce their price of the vaccine Rotarix and urge other suppliers to follow suit and cut their prices. We are very clear that more affordable vaccines mean increased vaccination rates benefitting the world's children."

GSK has committed to supply 125 million doses of RotarixTM to GAVI over the next 5 years at a 95% reduction of the price to developed Western markets to help meet the demand for rotavirus vaccination forecasted by UNICEF. The discounted RotarixTM price is in line with GSK's long-standing tiered pricing policy which enables poorer countries to pay significantly less than higher income countries for the same vaccine, with the lowest prices reserved for agencies such as UNICEF which purchase large volumes of vaccines for the world's poorest children.

Vaccination against rotavirus has so far been successfully introduced in four GAVI eligible countries: Nicaragua, Honduras, Bolivia and Guyana. By securing a guaranteed supply of low priced high quality vaccines, this new offer would enable GAVI to expand rotavirus vaccination further, with the aim to cover over 40 countries by 2015.

  • Diarrhoea is the second leading cause of death in children under five years of age worldwide(3) and rotavirus is the leading cause of severe diarrhoeal disease in children.(2)
  • Rotavirus has a devastating effect. It is estimated that more than half a million children die of rotavirus gastroenteritis each year - the equivalent of a child a minute worldwide(1) - and it is responsible for the hospitalization of millions more.(2) Most (around 85%) of these deaths occur in Africa and Asia.(5)
  • Growing evidence suggests that the introduction of rotavirus vaccines substantially reduce severe diarrhoea in young children. In Brazil, following the launch of RotarixTM, hospitalisations due to rotavirus gastroenteritis decreased by almost 60% just one year after the introduction of universal mass vaccination.(6)
  • In April 2009, the World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) recommended that rotavirus vaccination be included in all national immunisation programmes. Based on this decision, the WHO awarded global prequalification to Rotarix™. These decisions have opened the door to making rotavirus vaccines available to children worldwide.
  • 100 million doses of RotarixTM have been delivered since its first launch in 2007 which means that around 50 million children across the world have been vaccinated with RotarixTM against rotavirus.
  • Vaccination against rotavirus has so far been successfully introduced in 14 countries in Latin America and Mexico, including four GAVI eligible countries: Nicaragua, Honduras, Bolivia and Guyana. South Africa is the only country in Africa to currently vaccinate against rotavirus, with North Sudan expected to follow in June 2011.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

1. World Health Organisation. Weekly epidemiological record 2011; 86: 173-176
2. Forster J et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123: e393-e400
3. Black R et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969-1987
4. GAVI Alliance (2009). Pneumococcal AMC: Frequently asked questions. Accessed 3 June 2011 from: www.vaccineamc.org/files/FAQs2009.pdf
5. Parashar U et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003; 9(5): 565-572
6. Safadi M et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Brazil. Poster presentation at ESPID. www.kenes.com/espid09/posters/abstract660.htm (accessed 9 May 2011)

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...